In a report issued on June 17, George Hill from Deutsche Bank maintained a Sell rating on Rite Aid (RAD – Research Report), with a price target of $4.00. The company’s shares closed last Friday at $6.20, close to its 52-week low of $4.68.
According to TipRanks.com, Hill is a 4-star analyst with an average return of 5.5% and a 51.5% success rate. Hill covers the Healthcare sector, focusing on stocks such as AmerisourceBergen, Molina Healthcare, and 1Life Healthcare.
The word on The Street in general, suggests a Strong Sell analyst consensus rating for Rite Aid with a $5.33 average price target.
The company has a one-year high of $21.68 and a one-year low of $4.68. Currently, Rite Aid has an average volume of 4.19M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rite Aid Corp. engages in the ownership and management of retail drug stores. It operates through the Retail Pharmacy and Pharmacy Services business segments. The Retail Pharmacy segment includes branded and generic prescription drugs, health and beauty aids, personal care products, and walk-in retail clinics. The Pharmacy Services segment offers transparent and traditional pharmacy benefit management for insurance companies, employers, health plans, and government employee groups. The company was founded by Alex Grass in September 1962 and is headquartered in Camp Hill, PA.
Read More on RAD:
- Mizuho Securities Keeps a Buy Rating on Southwestern Energy (SWN)
- Mizuho Securities Reaffirms Their Buy Rating on Comstock Resources (CRK)
- Mizuho Securities Keeps Their Hold Rating on Range Resources (RRC)
- Mizuho Securities Keeps Their Buy Rating on Coterra Energy (CTRA)
- Walgreens Boots Alliance (WBA) Gets a Hold Rating from Deutsche Bank